Inhaled Insulin: A Clinical and Historical Review

Cardiology in Review

Volumn 25, Issue 3, 2017, Pages 140-146

  Chan, Jason ^a   Cheng Lai, Angela ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Afrezza; diabetes; history; inhaled insulin; technosphere

Indexed keywords

HEMOGLOBIN A1C; INSULIN; RECOMBINANT HUMAN INSULIN; ANTIDIABETIC AGENT;

BLOOD GLUCOSE MONITORING; CANCER RISK; COUGHING; DIABETES MELLITUS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INTERACTION; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INHALATION; INSULIN TREATMENT; LUNG CIRCULATION; MAXIMUM PLASMA CONCENTRATION; PARTICLE SIZE; PATIENT COMPLIANCE; PHARMACODYNAMICS; POWDER INHALER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CLINICAL PHARMACOLOGY; HISTORY; INHALATIONAL DRUG ADMINISTRATION; PHARMACOLOGY;

ADMINISTRATION, INHALATION; DIABETES MELLITUS; HISTORY, 20TH CENTURY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PHARMACOLOGY; PHARMACOLOGY, CLINICAL;

EID: 85017408911     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0000000000000143     Document Type: Review

References (39)

1. World Health Organization. Diabetes: fact sheet (no. 312). Available at: http://www.who.int/mediacentre/factsheets/fs312/en/. Published November 2016. Accessed November 28, 2016.
2. García-Pérez LE, Alvarez M, Dilla T, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4:175-194.
3. Jha AK, Aubert RE, Yao J, et al. Greater adherence to diabetes drugs is linked to less hospital use and could save nearly 5 billion annually. Health Aff (Millwood). 2012;31:1836-1846.
4. Murray P, Chune GW, Raghavan VA. Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trials. Curr Atheroscler Rep. 2010;12:432-439.
5. Traynor K. Inhaled insulin product approved. Am J Health Syst Pharm. 2014;71:1238.
6. Afrezza® (insulin human) inhalation powder [package insert]. Danbury, CT: Mannkind Corporation; June 2014. US Food and Drug Administration website. Available at: https://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022472lbl.pdf. Accessed December 17, 2016.
7. Møller N, Nair KS. Diabetes and protein metabolism. Diabetes. 2008;57:3-4.
8. Helmstädte, A. Antidiabetic drugs used in Europe prior to the discovery of insulin. Pharmazie. 2007;62:717-720.
9. Mazur A. Why were starvation diets promoted for diabetes in the pre-insulin period? Nutr J. 2011;10:23.
10. Karamitsos DT. The story of insulin discovery. Diabetes Res Clin Pract. 2011;93(suppl 1):S2-S8.
11. Yaturu S. Insulin therapies: current and future trends at dawn. World J Diabetes. 2013;4:1-7.
12. Kim ES, Plosker GL. AFREZZA® (insulin human) inhalation powder: a review in diabetes mellitus. Drugs. 2015;75:1679-1686.
13. Fala L. Afrezza (Insulin Human) inhalation powder approved for the treatment of patients with type 1 or type 2 diabetes. Am Health Drug Benefits. 2015;8(Spec Feature):40-43.
14. Donnelly LA, Morris AD, Evans JM; DARTS/MEMO collaboration. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM. 2007;100:345-350.
15. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218-1224.
16. Polonsky WH, Hajos TR, Dain MP, et al. Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population. Curr Med Res Opin. 2011;27:1169-1174.
17. Verma A, Kumar N, Malviya R, et al. Emerging trends in noninvasive insulin delivery. J Pharm (Cairo). 2014;2014:378048.
18. Beaser RS, Hollander PA, Silvestri R. Inhaled insulin: pulmonary considerations. Medscape CME May 21, 2007. Available at https://nutritionj.biomedcentral.com/articles/10.1186/1475-2891-10-23. Accessed May 19, 2016.
19. Santos Cavaiola T, Edelman S. Inhaled insulin: a breath of fresh air? A review of inhaled insulin. Clin Ther. 2014;36:1275-1289.
20. Shah RB, Patel M, Maahs DM, et al. Insulin delivery methods: Past, present and future. Int J Pharm Investig. 2016;6:1-9.
21. Derosa G, Maffioli P. Inhaled insulin: weighing the pros and cons. Lancet Diabetes Endocrinol. 2015;3:834-835.
22. Mastrandrea LD. Inhaled insulin: overview of a novel route of insulin administration. Vasc Health Risk Manag. 2010;6:47-58.
23. Mospan CM, Leonard C, Alley K. When should a provider consider insulin human inhalation powder? JAAPA. 2016;29:16-18.
24. Mack GS. Pfizer dumps Exubera. Nat Biotechnol. 2007;25:1331-1332.
25. Ledet G, Graves RA, Bostanian LA, et al. A second-generation inhaled insulin for diabetes mellitus. Am J Health Syst Pharm. 2015;72:1181-1187.
26. Grant ML, Grayson WS, Paul M, inventors; Mannkind Corporation, assignee. Diketopiperazine microparticles with defined specific surface areas. US patent 8,551,528 B2. October 8, 2013.
27. Pfützner A, Forst T. Pulmonary insulin delivery by means of the technosphere drug carrier mechanism. Expert Opin Drug Deliv. 2005;2:1097-1106.
28. Setji TL, Hong BD, Feinglos MN. Technosphere insulin: inhaled prandial insulin. Expert Opin Biol Ther. 2016;16:111-117.
29. Leahy JL. Technosphere inhaled insulin: is faster better? Diabetes Care. 2015;38:2282-2284.
30. Levemir® (insulin detemir [rDNA origin] injection) [package insert]. Princeton, NJ: Novo Nordisk Inc; June, 2005. US Food and Drug Administration website. Available at: http://www.accessdata.fda.gov/drugsatfda- docs/label/2007/021536s015lbl.pdf. Accessed January 10, 2017.
31. Insulin glargine. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. Accessed January 10, 2017.
32. Mannkind Corporation. Briefing document: Endocrinologic and metabolic drugs advisory committee. Available at: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM390865.pdf. Published April 1, 2016. Accessed November 29, 2016.
33. Bode BW, McGill JB, Lorber DL, et al; Affinity 1 Study Group. Inhaled technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015;38:2266-2273.
34. Rosenstock J, Franco D, Korpachev V, et al; Affinity 2 Study Group. Inhaled technosphere insulin versus inhaled technosphere placebo in insulin-naïve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents. Diabetes Care. 2015;38:2274-2281.
35. Future of Afrezza Inhaled insulin: Interview with Michael Castagna, CCO of MannKind Corp. Exclusive. Available at: http://www.medgadget. com/2016/10/future-of-afrezza-inhaled-insulin-interview-withmichael-castagna-cco-of-mannkind-corp.html. Accessed November 21, 2016.
36. Milstein R, Recerra NM, Shubrook JH. Insulin pumps: beyond basal-bolus. Cleve Clin J Med. 2015;82:835-842.
37. Lee JJ, Dassau E, Zisser H, et al. In silico evaluation of an artificial pancreas combining exogenous ultrafast-acting technosphere insulin with zone model predictive control. J Diabetes Sci Technol. 2013;7:215-226.
38. Zisser H, Dassau E, Lee JJ, et al. Clinical results of an automated artificial pancreas using technosphere inhaled insulin to mimic first-phase insulin secretion. J Diabetes Sci Technol. 2015;9:564-572.
39. Palmer E. Sanofi and MannKind terminate Afrezza partnership. Available at: http://www.fiercepharma.com/pharma/sanofi-and-mannkind-terminateafrezza-partnership. Accessed November 21, 2016.